Metastatic Bone Disease

Metastatic Bone Disease

Global Metastatic Bone Disease Market to Reach $27.6 Billion by 2030
The global market for Metastatic Bone Disease estimated at US$17.5 Billion in the year 2023, is expected to reach US$27.6 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Metastatic Bone Disease Medication, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$11.2 Billion by the end of the analysis period. Growth in the Radiation Therapy segment is estimated at 7.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $5.4 Billion, While China is Forecast to Grow at 6.3% CAGR
The Metastatic Bone Disease market in the U.S. is estimated at US$5.4 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.8 Billion by the year 2030 trailing a CAGR of 6.3% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.3% and 5.4% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 5.4% CAGR.

What to Expect from the Global Economy in 2024
Edgy geopolitics, and economic instability caused by monetary policy tightening and ensuing higher interest rates will create a tumultuous landscape for 2024. Several factors will continue to exert pressure on the path to recovery including hostilities in the Middle East and increasingly common climate disasters. Among the risks, several positives are also taking shape such as growing signs of disinflation and easing of anxiety over stubborn inflation, supply chain normalization and price moderation despite volatility in energy costs. Elections across several G21 jurisdictions, notably in India and the United States, will have potential ramifications for capital flows and investment strategies. While India emerges as a compelling destination in the global investment landscape, U.S, based tech firms will continue to dominate, fueled by a dynamic ecosystem of talent and capital. Tech opportunities in Silicon Valley and beyond remain attractive for investors seeking high-growth prospects supported largely by a resilient albeit slowing domestic economy and conducive regulatory environment. Europe will continue to battle tight monetary policy and recession risks with U.K. having the most challenging outlook and running the greatest risk of recession in 2024. China remains a wild card with hope for growth in the country underpinned by government spending and improvements in consumer spending. The volatile environment will offer both opportunities and challenges for investors and businesses alike. Embracing volatility as a catalyst for growth together with agility and strategic foresight in navigating investment decisions will remain important for survival.

Select Competitors (Total 42 Featured) -
  • Amgen, Inc.
  • Bayer AG
  • Boston Scientific Corporation
  • BTG PLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Medtronic PLC
  • Merck & Co., Inc.
  • Novartis International AG
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Metastatic Bone Disease - Global Key Competitors Percentage Market Share in 2024 (E)
Global Economic Update
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Metastatic Bone Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 2: World Historic Review for Metastatic Bone Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 3: World 16-Year Perspective for Metastatic Bone Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 5: World Historic Review for Medication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 6: World 16-Year Perspective for Medication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 8: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 9: World 16-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Surgical Intervention by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 11: World Historic Review for Surgical Intervention by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 12: World 16-Year Perspective for Surgical Intervention by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for Tumor Ablation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 14: World Historic Review for Tumor Ablation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 15: World 16-Year Perspective for Tumor Ablation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Breast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 17: World Historic Review for Breast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 18: World 16-Year Perspective for Breast by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 20: World Historic Review for Lung by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 21: World 16-Year Perspective for Lung by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Thyroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 23: World Historic Review for Thyroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 24: World 16-Year Perspective for Thyroid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 25: World Recent Past, Current & Future Analysis for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 26: World Historic Review for Kidney by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 27: World 16-Year Perspective for Kidney by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Prostate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 29: World Historic Review for Prostate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 30: World 16-Year Perspective for Prostate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 31: World Recent Past, Current & Future Analysis for Other Origin of Metastasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 32: World Historic Review for Other Origin of Metastasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 33: World 16-Year Perspective for Other Origin of Metastasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 35: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 36: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 37: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 38: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 39: World 16-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 40: World Recent Past, Current & Future Analysis for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 41: World Historic Review for Ambulatory Surgical Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 42: World 16-Year Perspective for Ambulatory Surgical Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
TABLE 43: World Metastatic Bone Disease Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
III. MARKET ANALYSIS
UNITED STATES
Metastatic Bone Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 44: USA Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: USA Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: USA 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: USA Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: USA 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: USA Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: USA 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
CANADA
TABLE 53: Canada Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Canada 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Canada 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Canada 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
JAPAN
Metastatic Bone Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 62: Japan Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Japan 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 65: Japan Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Japan 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: Japan 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
CHINA
Metastatic Bone Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 71: China Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: China Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: China 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 74: China Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: China Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: China 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 78: China Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: China 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
EUROPE
Metastatic Bone Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 80: Europe Recent Past, Current & Future Analysis for Metastatic Bone Disease by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 81: Europe Historic Review for Metastatic Bone Disease by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Europe 16-Year Perspective for Metastatic Bone Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 83: Europe Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Europe Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Europe 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Europe 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Europe 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
FRANCE
Metastatic Bone Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 92: France Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: France Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: France 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 95: France Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 96: France Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: France 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: France Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: France 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
GERMANY
Metastatic Bone Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 101: Germany Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Germany Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Germany 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 104: Germany Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Germany Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Germany 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 107: Germany Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Germany Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Germany 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
ITALY
TABLE 110: Italy Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: Italy Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: Italy 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 113: Italy Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Italy Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Italy 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Italy Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Italy 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
UNITED KINGDOM
Metastatic Bone Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 119: UK Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 120: UK Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 121: UK 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 122: UK Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 123: UK Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 124: UK 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 125: UK Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 126: UK Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 127: UK 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 129: Rest of Europe Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 130: Rest of Europe 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 132: Rest of Europe Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 133: Rest of Europe 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 135: Rest of Europe Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 136: Rest of Europe 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Metastatic Bone Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 138: Asia-Pacific Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 139: Asia-Pacific 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 141: Asia-Pacific Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 142: Asia-Pacific 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 144: Asia-Pacific Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 145: Asia-Pacific 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
REST OF WORLD
TABLE 146: Rest of World Recent Past, Current & Future Analysis for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 147: Rest of World Historic Review for Metastatic Bone Disease by Treatment - Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 148: Rest of World 16-Year Perspective for Metastatic Bone Disease by Treatment - Percentage Breakdown of Value Sales for Medication, Radiation Therapy, Surgical Intervention and Tumor Ablation Therapy for the Years 2014, 2024 & 2030
TABLE 149: Rest of World Recent Past, Current & Future Analysis for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 150: Rest of World Historic Review for Metastatic Bone Disease by Origin Of Metastasis - Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 151: Rest of World 16-Year Perspective for Metastatic Bone Disease by Origin Of Metastasis - Percentage Breakdown of Value Sales for Breast, Lung, Thyroid, Kidney, Prostate and Other Origin of Metastasis for the Years 2014, 2024 & 2030
TABLE 152: Rest of World Recent Past, Current & Future Analysis for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 153: Rest of World Historic Review for Metastatic Bone Disease by End-Use - Hospitals, Specialty Clinics and Ambulatory Surgical Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 154: Rest of World 16-Year Perspective for Metastatic Bone Disease by End-Use - Percentage Breakdown of Value Sales for Hospitals, Specialty Clinics and Ambulatory Surgical Centers for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings